Biotechnology News and Research

RSS

Planisware version 5.2 Product Portfolio Management module released

Planisware, the leading global provider of world-class project and portfolio management (PPM) solutions recently announced the release of Planisware 5.2. Available immediately, Planisware 5.2 is the organization's most ambitious release to date and features more enhancements and upgrades than any previous Planisware version.

19 Feb 2011

New tuberculosis vaccine provides better protection

Nele Festjens and Nico Callewaert of VIB and Ghent University have improved the efficacy of the vaccine for tuberculosis. The new vaccine affords - as already proven in mice - better protection against the disease. The development of a new tuberculosis vaccine is a priority in the fight against the disease which claims the lives of 1.7 million people each year. The current vaccine provides only partial protection.

19 Feb 2011

Biocare, HJF sign license agreement to distribute antibody against prostate cancer

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has signed a licensing agreement with Biocare Medical, a biotechnology company based in Concord, Calif., for the exclusive worldwide sales and distribution rights for the immunohistochemistry of an antibody designed to detect tumor prevalence in prostate cancer patients.

18 Feb 2011

USPTO issues two patents to VIRxSYS SMaRT RNA platform technology

VIRxSYS Corporation, a privately-held biotechnology company with proprietary RNA payload and lentiviral vector delivery platform technologies, today announced that the United States Patent and Trademark Office has issued the Company two patents for its SMaRT RNA platform technology, capable of reprogramming or repairing genes to create, increase or change protein expression.

18 Feb 2011

BioMimetic highlights updates on orthopedic and rehabilitation devices during AAOS meeting

BioMimetic Therapeutics, today announced highlights from its analyst and investor meeting which was held on Thursday, February 17 in San Diego, CA in conjunction with the American Academy of Orthopedic Surgery Annual Meeting.

18 Feb 2011

DiaGenic fourth quarter operating revenue increases to NOK 1,078 thousand

DiaGenic has significantly altered its business strategy during 2010 to leverage more effectively its commercial potential, and strengths in Intellectual Property (IP). The Company has made significant progress in its business activities towards big pharma since implementation of the new strategy. DiaGenic is well positioned as a multimodal partner with large pharma and imaging companies.

18 Feb 2011

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Exelixis, Inc. today reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial.

18 Feb 2011

China-Biotics applies 5 new patents for probiotics supplement, preparation

China-Biotics, Inc., the leading developer, manufacturer and distributor of probiotics products in China, today announced it has applied for 5 new patents through its wholly owned subsidiary Growing Bioengineering to the State Bureau of Intellectual Property.

18 Feb 2011

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Apricus Biosciences, Inc., announced today that it is currently in discussions with the U.S. Food and Drug Administration ("FDA") relating to the PrevOnco™ Special Protocol Assessment ("SPA") Phase III protocol submitted by the Company in December 2010.

18 Feb 2011

Iris Pharma announces validation of new EIU model of ocular inflammation

Iris Pharma, a world leader CRO specialized in ophthalmology, today announced the validation of the Endotoxin-Induced Uveitis model, a new model of ocular inflammation.

17 Feb 2011

Benitec strengthens patent position in RNAi

Benitec Limited (ASX: BLT), (PINK:BNIKF), a world leader in expressed gene silencing for human therapeutics, is pleased to announce that the United States Patent and Trademark Office (USPTO) has today indicated that it is issuing the Re-examination Certificate, the formal final step in the USPTO’s confirmation of patentability of claims in the key ‘099 Graham Patent [US Patent No. 6,573,099] "Genetic Constructs for Delaying or Repressing the Expression of a Target Gene", the wide-ranging platform technology patent covering the use of expressed RNA interference (RNAi) in human therapeutic applications.

17 Feb 2011

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2010.

17 Feb 2011

Researchers find blue-green algae may be responsible for producing estrogen-like compound in water

University of Tennessee, Knoxville, researchers have found that blue-green algae may be responsible for producing an estrogen-like compound in the environment which could disrupt the normal activity of reproductive hormones and adversely affect fish, plants and human health.

17 Feb 2011

First evidence of neurotrophic factors improving status of degenerating dopamine neurons in Parkinson's brains

Ceregene, Inc., a biopharmaceutical company, reported today that its scientists and collaborators have published new experimental findings in support of its Parkinson's disease program which appeared as the lead article in the current issue of Movement Disorders. The publication reports the first evidence that gene transfer can provide targeted expression of a neurotrophic factor, i.e., neurturin or NRTN, intended to restore and preserve dying neurons.

17 Feb 2011

ASN opposes proposed $1.6 billion reduction to NIH budget

Proposed cuts to the National Institutes of Health (NIH) budget for 2011 will limit the nation's ability to advance patient care and public health.

17 Feb 2011

EMA publishes concept paper on pharmaceutical cold storage conditions during transport

The European Medicines Agency has published a concept paper on storage conditions during transport. The goal is to create new Good Distribution Practice and GMP guidance and may lead to the need to revise the guideline on declaration of storage conditions.

From IQPC Ltd 17 Feb 2011

FDA, Threshold enter agreement on SPA for TH-302 Phase 3 trial in patients with soft tissue sarcoma

Threshold Pharmaceuticals, Inc. today announced that the Company reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a Phase 3 randomized trial of TH-302 in patients with soft tissue sarcoma.

17 Feb 2011

Oncolytics begins enrollment in 2-Arm carboplatin Phase II randomized study for pancreatic cancer

Oncolytics Biotech Inc. announced today that enrollment has begun in a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer.

17 Feb 2011

MedImmune, PDL BioPharma enter definitive agreement to resolve legal patent disputes

PDL BioPharma, Inc. today announced that PDL and MedImmune, LLC have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to MedImmune's product Synagis and PDL's patents known as the Queen et al. patents.

17 Feb 2011

New fully human monoclonal antibodies to battle Chikungunya

The Singapore Immunology Network (SIgN), an institute of the Agency of Science, Technology and Research (A*STAR), and VIVALIS, a French biopharmaceutical company, announced today the discovery of two new fully human monoclonal antibodies which could battle Chikungunya, a disease that currently has no available vaccine or specific treatment.

16 Feb 2011

Biotechnology News and Research

Planisware version 5.2 Product Portfolio Management module released

New tuberculosis vaccine provides better protection

Biocare, HJF sign license agreement to distribute antibody against prostate cancer

USPTO issues two patents to VIRxSYS SMaRT RNA platform technology

BioMimetic highlights updates on orthopedic and rehabilitation devices during AAOS meeting

DiaGenic fourth quarter operating revenue increases to NOK 1,078 thousand

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

China-Biotics applies 5 new patents for probiotics supplement, preparation

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Iris Pharma announces validation of new EIU model of ocular inflammation

Benitec strengthens patent position in RNAi

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Researchers find blue-green algae may be responsible for producing estrogen-like compound in water

First evidence of neurotrophic factors improving status of degenerating dopamine neurons in Parkinson's brains

ASN opposes proposed $1.6 billion reduction to NIH budget

EMA publishes concept paper on pharmaceutical cold storage conditions during transport

FDA, Threshold enter agreement on SPA for TH-302 Phase 3 trial in patients with soft tissue sarcoma

Oncolytics begins enrollment in 2-Arm carboplatin Phase II randomized study for pancreatic cancer

MedImmune, PDL BioPharma enter definitive agreement to resolve legal patent disputes

New fully human monoclonal antibodies to battle Chikungunya

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News